Kailera Therapeutics (KLRA) news
Recent news
Shares of Kailera Therapeutics up 1% after weight-loss drug meets main goal of late-stage trials in China
Shares of Kailera Therapeutics (Nasdaq: KLRA) rose 1% following the announcement that its weight-loss drug, HRS-9531 (KAI-9531), met its primary endpoints in a late-stage clinical trial conducted in China. The Phase 3 GEMINI-1 trial, led by partner Hengrui Pharma, demonstrated significant weight…
AInvest Wire · Jul 7, 2026Shares of Kailera Therapeutics up 1.9% premarket after weight-loss drug meets main goal of late-stage trials in China
Shares of Kailera Therapeutics (NASDAQ: KLRA) rose 1.9% in premarket trading following the announcement that its lead drug candidate, ribupatide, met its primary endpoint in late-stage trials conducted in China. The Phase 2 trial, which involved 8 mg of ribupatide administered weekly, resulted in a…
AInvest Wire · Jul 7, 2026Kailera Therapeutics announces positive topline data from two Henrui Pharma Phase 3 clinical trials of oral small molecule GLP-1 receptor agonist HRS-7535/KAI-7535
AInvest Wire · Jul 7, 2026Biomer's IPO is said to draw nearly 220 institutional orders
Biomer, a biotechnology firm, has attracted nearly 220 institutional orders for its upcoming initial public offering (IPO), signaling strong interest from professional investors. The company’s ability to draw such a broad base of institutional support reflects market appetite for biotech firms with…
AInvest Wire · May 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.